SRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SRI is not a good buy right now for an impatient trader. The setup lacks a strong proprietary buy signal, hedge funds are aggressively selling, options positioning is slightly bearish (puts > calls), and the technicals show only a mild upswing that’s losing momentum into nearby resistance. I would avoid initiating a new long here; only holders should consider holding rather than adding.
Price/Trend: Post-market at 6.58 after a -1.50% regular-session drop, suggesting near-term supply. Momentum: MACD histogram is above 0 (bullish bias) but positively contracting, which often signals weakening upside momentum rather than acceleration. RSI(6)=60.5 (neutral-to-slightly-bullish), not an oversold bounce zone. Moving Averages: Converging MAs indicate consolidation/chop rather than a clean trend. Levels: Pivot 6.328 is the near-term line to hold; resistance sits at R1 6.839 then R2 7.155. Support is S1 5.817 then S2 5.501. With price below/near R1 and momentum fading, risk/reward for an immediate buy is unattractive. Quant pattern read-through: similar-pattern stats imply ~-1.35% over the next month (weak forward edge).
Intellectia Proprietary Trading Signals
Losses are narrowing YoY (EPS and net income improved), which can support a turnaround narrative. Next earnings date (2026-02-25 pre-market) is the next potential event catalyst if results/guide surprise positively.
Hedge funds are selling heavily (selling amount up ~725.81% QoQ), a meaningful sentiment/flow headwind. Revenue declined YoY in the latest quarter, and gross margin slipped, implying operating improvement is not yet driven by top-line strength. Options open interest skews slightly bearish (P/C>1). No supportive news flow in the past week, so there’s no near-term catalyst to force a breakout. Nearby resistance at ~6.84 with weakening MACD momentum raises the odds of chop/pullback rather than an immediate move higher.
Latest quarter: 2025/Q3. Revenue: 210.267M, down -1.67% YoY (soft top-line). Profitability: Net income improved to -9.371M (still a loss, but 32.55% better YoY) and EPS improved to -0.34 (+30.77% YoY), indicating cost/efficiency progress. Margins: Gross margin 20.77%, down -0.48% YoY—still a slight deterioration, so the turnaround is not yet margin-led. Overall: improving losses but not yet a clean growth inflection.
Recent change: On 2025-11-13, Barrington’s Gary Prestopino reiterated Outperform but cut the sum-of-the-parts valuation range to $13–$16 (from $16) and reduced 2025/2026 adjusted EBITDA estimates (to $30M and $40.6M from $34M and $51M). Wall Street pro view: bullish rating is a plus. Con view: target/range and EBITDA cuts show reduced confidence in near-term fundamentals. Net: supportive long-term angle, but the direction of estimate revisions is negative.
